It's asinine. It would destroy many oil Cos in the U.S.. Oil Cos have brought a lot of good jobs and wealth to many people around the world, they are not the enemy as the Democrats portray. Socialists bottom line just destroy wealth.
Costs are escalating for this one pony show that has effective alternatives and more competition on the horizon.
Not a good sign.
Back to the lows of the day.
I am always amazed.
Oil Going to the low $20's Market will break the 1827 area, S&P next top 1350. AAPL will be dumped tomorrow. Nothing but pumping on CNBC by folks holding the stock.
A lot of big boys have to get out.
Outlook revised down.
Those are very likely PTs. I was just pointing out the next 2 levels of support. But if I jumped to your PT's., I'd be ridiculed. What is coming will be much worse than the last big market downturn IMHO.
It will be difficult for biotechs. They get more punished by market revaluations especially with recession fears and FED hikes. Then you throw on this bone headed move of the shelf and the go it alone approach. I think $15 the next drop. Depending on the continued fears then around $9. maybe lower, maybe not. We could see some pops in between at or around support levels even now. The issue with tomorrow's open is all the Chinese data coming out on GDP etc. Its a big wild card.
I think our legal team is about to give Rosen a major body blow.
This should be $20--$30 now. It Will get there. Rosen must have realized that the Mako article was bogus, so the only thing left were Leo's letters. Rosen needs something to mitigate a counter suit for damages, problem for Rosen is this wasn't in the initial filing when the damages occurred. I don't see anything that was materially disclosed by Leo, sorry Bite, found it to be inane. Our defense team will rip this apart, they are first rate. I am surprised at what a joke Rosen really is...I mean I kept looking for any merit to this thinking there must be more. Ok the addendum complaint must be it...NOT. Also think Leo is doing a great job..bite.
Your projections are too low. You still need to breakdown your numbers by treatment, volume assumptions. Taska alone is worth double your projection if you compare the $809M buyout by Actavis (full price with CVRs) of DRTX for Dalvance now owned by AGN. I do think this is going lower though. You point out some high risks that now need to be factored into the PT. The market has a way of baiting people into buying when it is clearly going down.
an apology to Pharmjedi. You were right. I'll get back in $9-$10 as Pro. Good luck to you all!